DiaMedica Therapeutics Inc. (DMAC) PT Lowered to $14 at Lake Street Capital Markets

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to DiaMedica Therapeutics Inc. (DMAC) PT Lowered to $14 at Lake Street Capital Markets

DiaMedica Therapeutics Inc. (DMAC) Reports Q4 Results, Issues Business Update

March 14, 2022 4:46 PM EDT

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the year ended December 31, 2021. Management will host a conference call Tuesday, March 15, 2022, at 8:00AM Eastern Time / 7:00AM Central Time, to discuss its business update and full year financial results.

Our clinical, regulatory, financial and team building achievements in 2021 have laid a solid foundation for success, said Rick Pauls, CEO of DiaMedica. In 2022, our team is focused on executing on our Phase 2/3 ReMEDy2... More